FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2938231313> ?p ?o ?g. }

• W2938231313 abstract "Background Black patients have an increased prevalence and severity of systemic lupus erythematosus (SLE), alongside higher mortality rates. The efficacy and safety of intravenous (IV) belimumab has been demonstrated in several Phase 2/3 studies; however, the small number of black patients within these trials, and the conflicting results, have limited conclusions regarding efficacy in this population. The objective of this study was to specifically assess the efficacy and safety of IV belimumab plus standard of care (SoC) in black patients with active, auto antibody-positive SLE. Methods EMBRACE (NCT01632241) is a randomized, multicenter, double-blind, placebo-controlled trial in patients of self identified black race, aged 18 years, with active SLE at screening. Patients were randomized (2:1) to monthly belimumab 10 mg/kg IV or placebo, plus SoC. The primary endpoint was the SLE Responder Index (SRI) response rate with modified SLEDAI-2K (S2K) scoring for proteinuria at Week 52 (SRI-S2K response required a 4 point reduction in the SELENA-SLEDAI (SS)-S2K, no worsening [increase of Results The mITT population comprised 448 patients; 96.9% were female and mean (SD) age was 38.8 (11.42) years. Although the study did not achieve the primary endpoint, numerical trends were observed in favor of belimumab, and significant improvements were observed in subgroups with characteristics of high disease activity (HDA; table). Study withdrawals were similar between groups (belimumab 22.4%; placebo 24.2%) and AEs were the primary reason for withdrawals (belimumab 5.4%; placebo 6.7%). The percentage of patients who experienced an AE (belimumab 83.7%; placebo 87.3%) or serious AE (belimumab 10.9%; placebo 18.8%) was similar between groups. Two deaths occurred within the belimumab group (0.6%; pneumonia and meningitis); neither were established as directly related to belimumab. Conclusions Whilst the primary endpoint of this study in black patients with SLE was not achieved, improvements in favor of belimumab were observed, with significant benefits in patients with HDA. The safety profile was acceptable and consistent with previous studies. Funding Source(s): Study (BEL115471) funded by GSK." @default.
• W2938231313 created "2019-04-25" @default.
• W2938231313 creator A5005565004 @default.
• W2938231313 creator A5012742212 @default.
• W2938231313 creator A5023279987 @default.
• W2938231313 creator A5025335653 @default.
• W2938231313 creator A5026822726 @default.
• W2938231313 creator A5035308045 @default.
• W2938231313 creator A5036222488 @default.
• W2938231313 creator A5047601269 @default.
• W2938231313 creator A5048973709 @default.
• W2938231313 creator A5055141120 @default.
• W2938231313 date "2019-04-01" @default.
• W2938231313 modified "2023-10-14" @default.
• W2938231313 title "200 Efficacy and safety of belimumab in patients of black race with systemic lupus erythematosus: results from the EMBRACE study" @default.
• W2938231313 doi "https://doi.org/10.1136/lupus-2019-lsm.200" @default.
• W2938231313 hasPublicationYear "2019" @default.
• W2938231313 type Work @default.
• W2938231313 sameAs 2938231313 @default.
• W2938231313 citedByCount "5" @default.
• W2938231313 countsByYear W29382313132019 @default.
• W2938231313 countsByYear W29382313132020 @default.
• W2938231313 countsByYear W29382313132021 @default.
• W2938231313 countsByYear W29382313132022 @default.
• W2938231313 crossrefType "proceedings-article" @default.
• W2938231313 hasAuthorship W2938231313A5005565004 @default.
• W2938231313 hasAuthorship W2938231313A5012742212 @default.
• W2938231313 hasAuthorship W2938231313A5023279987 @default.
• W2938231313 hasAuthorship W2938231313A5025335653 @default.
• W2938231313 hasAuthorship W2938231313A5026822726 @default.
• W2938231313 hasAuthorship W2938231313A5035308045 @default.
• W2938231313 hasAuthorship W2938231313A5036222488 @default.
• W2938231313 hasAuthorship W2938231313A5047601269 @default.
• W2938231313 hasAuthorship W2938231313A5048973709 @default.
• W2938231313 hasAuthorship W2938231313A5055141120 @default.
• W2938231313 hasBestOaLocation W29382313131 @default.
• W2938231313 hasConcept C159654299 @default.
• W2938231313 hasConcept C170286685 @default.
• W2938231313 hasConcept C177713679 @default.
• W2938231313 hasConcept C203014093 @default.
• W2938231313 hasConcept C2778453870 @default.
• W2938231313 hasConcept C2781205201 @default.
• W2938231313 hasConcept C59822182 @default.
• W2938231313 hasConcept C71924100 @default.
• W2938231313 hasConcept C76509639 @default.
• W2938231313 hasConcept C86803240 @default.
• W2938231313 hasConceptScore W2938231313C159654299 @default.
• W2938231313 hasConceptScore W2938231313C170286685 @default.
• W2938231313 hasConceptScore W2938231313C177713679 @default.
• W2938231313 hasConceptScore W2938231313C203014093 @default.
• W2938231313 hasConceptScore W2938231313C2778453870 @default.
• W2938231313 hasConceptScore W2938231313C2781205201 @default.
• W2938231313 hasConceptScore W2938231313C59822182 @default.
• W2938231313 hasConceptScore W2938231313C71924100 @default.
• W2938231313 hasConceptScore W2938231313C76509639 @default.
• W2938231313 hasConceptScore W2938231313C86803240 @default.
• W2938231313 hasLocation W29382313131 @default.
• W2938231313 hasOpenAccess W2938231313 @default.
• W2938231313 hasPrimaryLocation W29382313131 @default.
• W2938231313 hasRelatedWork W1982924102 @default.
• W2938231313 hasRelatedWork W2060364585 @default.
• W2938231313 hasRelatedWork W2507931453 @default.
• W2938231313 hasRelatedWork W2588655590 @default.
• W2938231313 hasRelatedWork W2901325146 @default.
• W2938231313 hasRelatedWork W3080758062 @default.
• W2938231313 hasRelatedWork W4225133373 @default.
• W2938231313 hasRelatedWork W4229034713 @default.
• W2938231313 hasRelatedWork W4293741145 @default.
• W2938231313 hasRelatedWork W2145710929 @default.
• W2938231313 isParatext "false" @default.
• W2938231313 isRetracted "false" @default.
• W2938231313 magId "2938231313" @default.
• W2938231313 workType "article" @default.